Marketing a new prescription allergy drug: discussion guide

In prescription pharmaceuticals the person who consumes the product is almost never the person who chooses it or the one who pays for it. That split is the whole difficulty of this scenario, and an answer that names patients and doctors as the two consumers has walked past it.

Work out who actually makes the decision before deciding how to market to them. A patient experiences the symptom and asks for relief. A prescriber chooses the molecule. A payer, usually through a pharmacy benefit manager, decides which products its formulary covers and at what tier — and that decision governs whether a prescription written for your drug is filled, substituted or abandoned at the counter over cost. So the most consequential industry consumer here is not a hospital or a pharmacy chain; it is the organisation that controls formulary placement, and the strategy aimed at it is not advertising but evidence, pricing and rebate negotiation. Naming that as your industry consumer, and saying why, is the single strongest move available in this discussion. It also gives the buying-behaviour section something real to analyse, because a formulary committee's incentives are documented and a generic 'consumer' preference is not.

The scenario also fixes the hardest possible category, and reading it literally is worth doing. It says a new brand-name prescription drug to treat allergies. New and brand-name means under patent, priced accordingly, with a limited window. Allergies means the competition is not other branded products — it is cheap second-generation antihistamines that patients can buy over the counter without seeing anyone at all. Any strategy that ignores that substitution is describing a market that does not exist. The credible positioning arguments are narrow and therefore specific: a population the over-the-counter options fail, a differentiated safety or onset profile, or a delivery route the alternatives do not offer. Pick one and defend it. Note too that the individual consumer's price sensitivity here is about the copay rather than the list price, which is a different variable and one the payer sets.

The life cycle requirement is where most answers become generic, because introduction, growth, maturity and decline can be recited about any product. For a patented drug the curve has a dated event on it: loss of exclusivity, after which generic entry typically collapses both price and share within months. That turns decline from a slow fade into a cliff you can see coming, and it makes the maturity stage the one where the real decisions sit — building prescriber habit and brand recognition before the cliff, considering a reformulation, an authorised generic, or a switch to over-the-counter status. Mapping the stages onto that timeline rather than onto a textbook curve is what makes the section about this product. The introduction stage carries its own specific problem in this category — you are asking prescribers to write something for a condition they already treat cheaply, so launch is about giving them a reason to change a settled habit.

Two smaller instructions carry marks. The brief says to defend or argue your recommendations, which asks for a case rather than a list — name the strongest objection to your strategy and answer it, because a recommendation nobody could disagree with is not a recommendation. And it says to support the response using key points and examples from the Learning Resources, so the citations should be to the course materials rather than only to whatever was found by searching. Finally, worth knowing before writing any consumer-facing tactic: direct-to-consumer prescription advertising is legal in the United States but tightly regulated, and product claim advertisements must carry the drug's significant risks alongside its benefits. A campaign proposal that ignores that constraint is not implementable. Getting the regulatory constraint in early also strengthens the defence section, because it shows the recommendation was built inside the rules rather than trimmed to fit them afterwards.